ENVALITH
株式会社タムロン logo

Tamron Co.,Ltd.

7740・Prime Market・Precision Instruments

Official website
株式会社タムロン logo
Tamron Co.,Ltd.7740

Business

Tamron Co., Ltd. is a precision optics manufacturer founded in 1952, listed on the Tokyo Stock Exchange Prime Market. Its core business is the Photographic Equipment Business (approximately 71% of net sales), centered on interchangeable lenses for mirrorless and SLR cameras, complemented by the Surveillance & FA Business, which handles surveillance camera and FA lenses, and the Mobility & Healthcare, and Other Business, which covers lenses for in-vehicle cameras, medical applications, and drones—forming a three-segment structure. In addition to domestic manufacturing sites (Saitama and Aomori), the company has production bases in Vietnam (2 plants), China, and Hong Kong, and has built a global framework with sales subsidiaries in the United States, Europe, and India. Consolidated net sales for FY2025 (ending March 2025) were ¥85,071 million.

Business Model

Tamron generates revenue through two axes: in-house brand products and OEM supply. In the Photographic Equipment Business, the company maintains a highly profitable structure with an operating margin of 25.8%, and is accelerating its multi-platform strategy by supporting three lens mounts: Sony E, Nikon Z, and Canon RF. In the surveillance, in-vehicle, and medical fields, the company is entering growth markets as an industrial optical lens provider, diversifying its business portfolio. R&D expenses amounted to ¥7,313 million, driving deeper optical technology development and its application to new fields.

Company Strengths

In FY2025, the Photographic Equipment Business achieved net sales of ¥60,643 million, segment operating profit of ¥15,630 million, and an operating margin of 25.8%. The company maintained a high margin even under the headwind of declining OEM sales, supported by the added value of in-house brand products and continued cost reduction activities.

The company offers a product lineup compatible with three mounts: Sony E-mount, Nikon Z-mount, and Canon RF-mount. It launched 7 new models in 2024 and 6 new models in 2025, achieving double-digit sales growth in the Japanese, U.S., and Indian markets. In particular, it first entered the Canon RF-mount market in 2024, also introducing a high-magnification zoom lens for the first time.

In FY2025, the Mobility & Healthcare, and Other Business achieved growth in both revenue and profit. Net sales of Lenses for In-vehicle Cameras exceeded ¥10,000 million (approximately ¥10,000 million) for the first time, while Medical Lenses grew to approximately 1.5 times the previous period, surpassing ¥1,000 million (approximately ¥1,000 million) for the first time. The company is capturing the spread of ADAS and the growth of the minimally invasive medical market.

ENVALITH's Perspective

In Q1 FY2026 (ending March 2026), net sales were ¥18,485 million (down 5.0% year on year) and operating profit was ¥3,441 million (down 18.7% year on year), as sluggish sales of certain OEM products continued for more than two consecutive quarters. Achieving the full-year forecast (net sales of ¥91,000 million, operating profit of ¥18,500 million) will require a recovery in the OEM business within the Photographic Equipment Business from the second quarter onward. Q1 progress against the full-year forecast stood at only 20.3% for net sales and 18.6% for operating profit, indicating a structure weighted toward the second half, which warrants attention as a risk factor.

The Surveillance & FA Business and the Mobility & Healthcare, and Other Business both achieved double-digit growth in both revenue and profit, reflecting the results of business diversification efforts. Meanwhile, segment profit in the Photographic Equipment Business fell sharply to ¥2,390 million in Q1 (down 37.2% year on year), with operating margin declining to 21.1%. Rising raw material and utility costs, higher personnel expenses, and increased SG&A expenses from stronger R&D investment have combined to create cost pressures that outweigh the effects of cost reduction activities. As an external factor, the weaker yen (approximately ¥4 against the US dollar and approximately ¥23 against the euro) is boosting yen-denominated sales, but the benefit to profit has been limited.

Regarding the business environment from the second quarter onward, the company has identified as concerns the uncertainty surrounding trade policies in various countries, the impact on resource prices, logistics, and procurement stemming from the worsening situation in the Middle East, and the indirect effects of semiconductor shortages, while keeping its earnings forecast unchanged. In particular, US tariff policy could affect sales to North America (Q1: ¥2,813 million) and procurement costs, while in the Chinese market, excess inventory continues to weigh on photographic-related sales. On the other hand, Q1 results are said to have exceeded the plan, with strength in the industrial businesses serving as a buffer against downside risk.

Growth Strategy

Aiming for a V-shaped recovery and achievement of medium-term plan targets through new product offensives, expansion of industrial businesses, and strengthening of the three-region production system

For 2026, the company targets the launch of 10 or more new products annually, having already released the A078 (large-aperture standard zoom) for Sony E and Nikon Z mounts in March. The lineup is being expanded through a multi-mount strategy, and revenue growth for the in-house brand continues in Japan, the U.S., and Europe. The European market was confirmed to have turned to recovery in Q1 FY2026 (ending March 2026).

Against a backdrop of rising demand for high-definition, high-resolution capabilities, Lenses for Surveillance Cameras have performed steadily. For Lenses for FA/Machine Vision, customer inventory adjustments have been completed and demand is recovering. Camera Modules have also seen expanded orders due to performance improvements. In Q1 FY2026 (ending March 2026), net sales were ¥3,602 million (up 25.2% year on year) and segment profit was ¥523 million (up 27.9% year on year), achieving double-digit growth in both revenue and profit.

The company is capturing robust demand for sensing lenses for in-vehicle cameras driven by the spread of ADAS, with the Chinese market also recovering. For Medical Lenses, an expanded product lineup leveraging ultra-small-diameter and thin-film technologies drove a significant increase in revenue of approximately 1.6 times year on year in Q1 FY2026 (ending March 2026). For the segment overall, net sales were ¥3,577 million (up 19.1% year on year) and profit was ¥901 million (up 23.7% year on year).

The company continues to promote cost reduction activities such as cost cutting and productivity improvement. Cost of sales in Q1 FY2026 (ending March 2026) was ¥10,276 million (down from ¥10,540 million in the same period of the previous year), showing certain results, but profit was pressured by an increase in selling, general and administrative expenses (¥4,767 million, versus ¥4,675 million in the same period of the previous year) due to soaring raw material costs and utility expenses, rising labor costs, and strengthened R&D investment. The challenge is to reach a level where cost reduction effects exceed the rise in external costs.

Last updated: July 17, 2026